Fig. 2From: Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study Change in CMT in the IVR and IVA groups. There was no significant change in CMT at 12 months post-treatment in the IVR group or in the IVA group (p = 0.53). CMT, central macular thickness; IVR, intravitreal injection of ranibizumab; IVA, intravitreal injection of afliberceptBack to article page